India’s Serum Institute Applies for Full Approval of Covishield Vaccine | World News

BENGALURU (Reuters) – Serum Institute Of India has applied to the country’s drug regulator and the health ministry for full market authorisation of its COVID-19 vaccine, Covishield, the company’s chief executive said in a tweet on Friday.

Serum Institute produces AstraZeneca’s COVID-19 vaccine under the brand name Covishield.

(Reporting by Shivani Singh in Bengaluru; Editing by Shounak Dasgupta)

Copyright 2021 Thomson Reuters.

Political Cartoons on World Leaders

Be the first to comment

Leave a Reply

Your email address will not be published.